Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors.

Yoichi Nakanishi, Koichi Takayama, Hiroshi Wataya, Miiru Izumi, Takahiro Minami, Koichi Takano, Koji Inoue, Shin'ichi Osaki, Kanehito Kimotsuki, Taishi Harada, Nobuyuki Hara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

BACKGROUND: Previous studies have reported a synergistic effect between irinotecan and cisplatin. We have conducted a phase I trial combining these agents to find the optimal dose of irinotecan in combination with a fixed dose of cisplatin. METHODS: Patients with advanced solid tumors, aged < or =75 years, performance status < or =2, and adequate organ function were enrolled in this study. They were treated at 4-week intervals with irinotecan plus 20 mg/m(2) cisplatin on days 1, 8, and 15. The starting dose of irinotecan of 40 mg/m(2) was escalated in 10 mg/m(2) increments until a maximum dose of 90 mg/m(2) was reached. RESULTS: The recommended dose for phase II studies is 90 mg/m(2) of irinotecan and 20 mg/m(2) of cisplatin on days 1, 8, and 15. Overall response to the chemotherapy was 35% (95% confidential interval, 19.2-54.6%). CONCLUSION: This combination seems to be active against lung cancer with acceptable toxicity. A phase II study is now ongoing.

Original languageEnglish
Pages (from-to)205-210
Number of pages6
JournalCHEMOTHERAPY
Volume48
Issue number4
DOIs
Publication statusPublished - Jan 1 2002

Fingerprint

irinotecan
Cisplatin
Neoplasms
Lung Neoplasms
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Nakanishi, Y., Takayama, K., Wataya, H., Izumi, M., Minami, T., Takano, K., ... Hara, N. (2002). Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors. CHEMOTHERAPY, 48(4), 205-210. https://doi.org/10.1159/000063866

Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors. / Nakanishi, Yoichi; Takayama, Koichi; Wataya, Hiroshi; Izumi, Miiru; Minami, Takahiro; Takano, Koichi; Inoue, Koji; Osaki, Shin'ichi; Kimotsuki, Kanehito; Harada, Taishi; Hara, Nobuyuki.

In: CHEMOTHERAPY, Vol. 48, No. 4, 01.01.2002, p. 205-210.

Research output: Contribution to journalArticle

Nakanishi, Y, Takayama, K, Wataya, H, Izumi, M, Minami, T, Takano, K, Inoue, K, Osaki, S, Kimotsuki, K, Harada, T & Hara, N 2002, 'Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors.', CHEMOTHERAPY, vol. 48, no. 4, pp. 205-210. https://doi.org/10.1159/000063866
Nakanishi, Yoichi ; Takayama, Koichi ; Wataya, Hiroshi ; Izumi, Miiru ; Minami, Takahiro ; Takano, Koichi ; Inoue, Koji ; Osaki, Shin'ichi ; Kimotsuki, Kanehito ; Harada, Taishi ; Hara, Nobuyuki. / Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors. In: CHEMOTHERAPY. 2002 ; Vol. 48, No. 4. pp. 205-210.
@article{02656610242847f395bf05e5bd911292,
title = "Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors.",
abstract = "BACKGROUND: Previous studies have reported a synergistic effect between irinotecan and cisplatin. We have conducted a phase I trial combining these agents to find the optimal dose of irinotecan in combination with a fixed dose of cisplatin. METHODS: Patients with advanced solid tumors, aged < or =75 years, performance status < or =2, and adequate organ function were enrolled in this study. They were treated at 4-week intervals with irinotecan plus 20 mg/m(2) cisplatin on days 1, 8, and 15. The starting dose of irinotecan of 40 mg/m(2) was escalated in 10 mg/m(2) increments until a maximum dose of 90 mg/m(2) was reached. RESULTS: The recommended dose for phase II studies is 90 mg/m(2) of irinotecan and 20 mg/m(2) of cisplatin on days 1, 8, and 15. Overall response to the chemotherapy was 35{\%} (95{\%} confidential interval, 19.2-54.6{\%}). CONCLUSION: This combination seems to be active against lung cancer with acceptable toxicity. A phase II study is now ongoing.",
author = "Yoichi Nakanishi and Koichi Takayama and Hiroshi Wataya and Miiru Izumi and Takahiro Minami and Koichi Takano and Koji Inoue and Shin'ichi Osaki and Kanehito Kimotsuki and Taishi Harada and Nobuyuki Hara",
year = "2002",
month = "1",
day = "1",
doi = "10.1159/000063866",
language = "English",
volume = "48",
pages = "205--210",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors.

AU - Nakanishi, Yoichi

AU - Takayama, Koichi

AU - Wataya, Hiroshi

AU - Izumi, Miiru

AU - Minami, Takahiro

AU - Takano, Koichi

AU - Inoue, Koji

AU - Osaki, Shin'ichi

AU - Kimotsuki, Kanehito

AU - Harada, Taishi

AU - Hara, Nobuyuki

PY - 2002/1/1

Y1 - 2002/1/1

N2 - BACKGROUND: Previous studies have reported a synergistic effect between irinotecan and cisplatin. We have conducted a phase I trial combining these agents to find the optimal dose of irinotecan in combination with a fixed dose of cisplatin. METHODS: Patients with advanced solid tumors, aged < or =75 years, performance status < or =2, and adequate organ function were enrolled in this study. They were treated at 4-week intervals with irinotecan plus 20 mg/m(2) cisplatin on days 1, 8, and 15. The starting dose of irinotecan of 40 mg/m(2) was escalated in 10 mg/m(2) increments until a maximum dose of 90 mg/m(2) was reached. RESULTS: The recommended dose for phase II studies is 90 mg/m(2) of irinotecan and 20 mg/m(2) of cisplatin on days 1, 8, and 15. Overall response to the chemotherapy was 35% (95% confidential interval, 19.2-54.6%). CONCLUSION: This combination seems to be active against lung cancer with acceptable toxicity. A phase II study is now ongoing.

AB - BACKGROUND: Previous studies have reported a synergistic effect between irinotecan and cisplatin. We have conducted a phase I trial combining these agents to find the optimal dose of irinotecan in combination with a fixed dose of cisplatin. METHODS: Patients with advanced solid tumors, aged < or =75 years, performance status < or =2, and adequate organ function were enrolled in this study. They were treated at 4-week intervals with irinotecan plus 20 mg/m(2) cisplatin on days 1, 8, and 15. The starting dose of irinotecan of 40 mg/m(2) was escalated in 10 mg/m(2) increments until a maximum dose of 90 mg/m(2) was reached. RESULTS: The recommended dose for phase II studies is 90 mg/m(2) of irinotecan and 20 mg/m(2) of cisplatin on days 1, 8, and 15. Overall response to the chemotherapy was 35% (95% confidential interval, 19.2-54.6%). CONCLUSION: This combination seems to be active against lung cancer with acceptable toxicity. A phase II study is now ongoing.

UR - http://www.scopus.com/inward/record.url?scp=18744401392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18744401392&partnerID=8YFLogxK

U2 - 10.1159/000063866

DO - 10.1159/000063866

M3 - Article

C2 - 12218268

AN - SCOPUS:18744401392

VL - 48

SP - 205

EP - 210

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 4

ER -